Centre National De La Recherche Scientifique

Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Universite Paris 7

Institute Pasteur

Ministère Des Armées—direction Centrale Du Service De Sante Des Armée

Universite Paris Vii

Chantal Combredet

Frédéric Tangy

Philippe Despres

Marie-Pascale Frenkiel

Hugues Bedouelle

Marianne Lucas-Hourani

Erika Navarro-Sanchez

Marc Gregoire

Valérie Labrousse-Najburg

Jean-François Fonteneau

Michel Brahic

Jean-Baptiste Guillerme

Pierre Charneau

Jean-Claude Manuguerra

Nicolas Escriou

Sylvie Van Der Werf

Marie Pascale Frenkiel

Bernadette Crescenzo-Chaigne

Benoît Callendret

Jean-Michel Betton

Valérie Lorin

Sylvie Gerbaud

Ana Maria Burguiere

Saliha Azebi

Jean-François Delagneau

Monique Martin

Frederik Kunst

Marie Mura

Fréderic Tangy

Anastassia Komarova

Frederick Kunst

Valerie Labrousse-Najburg

Valérie Labrousse Najburg

Frederik Institut Pasteur Kunst

Frederik Inst Pasteur Bureau Des Brevets Et Inventions Kunst

Jean-Francois Fonteneau

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5' copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5&#x2032; copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases

The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.

Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy

The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.

The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.

Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection

The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also concerns the preparation of immunogenic compositions using said cDNA.

Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions

Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae infection

The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.

The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain, for example, the Schwarz strain. It also concerns the preparation of infectious recombinant viruses and immunogenic compositions using the cDNA.

The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.

Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications

The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

Strain of SARS-associated coronavirus and applications thereof

Chimeric poly peptides and the therapeutic use thereof against a Flaviviridae  infection

The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre- m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.

Growing community of inventors

Paris, France

Chantal Combredet